Dorzolamide: A Review

Authors:

Abstract
Major advances in pharmacological research have led to the introduction of four new and potent topical ocular hypotensive agents within the past few years. The federal government requires stringent premarket testing to prove efficacy and safety. These safety and efficacy studies are performed on a finite number of patients over a limited period of time. After a drug has come to market, however, many more patients are exposed to it. Subtle idiosyncrasies of new agents and unanticipated side effects become apparent. As clinicians, we must recognize these events and use them to help guide us with our patient management. Dorzolamide (Trusopt, Merck and Co., Inc., West Point, PA), the first topical carbonic anhydrase inhibitor, has been clinically available for nearly 2 years. Much clinical data have been published about dorzolamide since it was first released. A brief review of the physiology of carbonic anhydrase inhibitors and the history of the development of the topical preparations will precede the discussion of the clinical use of dorzolamide.

This publication has 42 references indexed in Scilit: